Oligometastatic Prostate Cancer-targeting
with radiation
Contents
 Oligometastatic Cancer –definition
 Rationale for metastatic directed therapy
 SABR –studies
 Trials
Definition
 No thoughtful/formal staging-UICC 8th edition doesn’t have a
an assigned prognostic group
 <=3 lesions outside pelvis
 <=5 lesions limited to lymph nodes/bones
 <=10 lesions with no visceral involvement
 Select studies defining the same
 Imaging also need to be standardized Tc99>>>PSMA PET-CT
 Synchronous vs Metachronous ?
Stereotactic Ablative Radiotherapy (SABR)
 5 studies –retrospective small number
 Most of the targets bones >>some visceral, nodes
 Only take away message is that it’s safe
 No G-III toxicity
 Even G-II quite low
 Local control pretty good –ablative
 Freedom from androgen deprivation 2 studies managed for 2-3 years
2 Trials
 STOMP (Surveillance or metastasis-directed Therapy for
OligoMetastatic Prostate cancer recurrence)
 ORIOLE trial (Observation Versus Stereotactic Ablative
RadiatIOn for OLigometastatic Prostate CancEr)
Note
 The STOMP trial showed a trend towards delayed ADT, but
failed to show a reduction in metastatic progression.
An important limitation of both the STOMP
and ORIOLE studies is that the investigators
were unable to account for length-bias and may
well have included metastatic patients with
slower growing disease.
(1) a method of external
beam radiotherapy
(EBRT) that
(2) accurately delivers a
(3) high dose of
irradiation in
(4) one or few treatment
fractions to an
(5) extracranial target.
 AAPM Task
Group 101
 ASTRO and ACR
SBRT DEFINITION
SBRT spine-mets
 67 yr old male case of Ca Prostate post-op with spine recurrence
(cord compression)-D5-D6 level
 Post tumor decompression/spine stabilization patient planned for
SBRT to D5-D6 level
 RT dose 30 Gy/ 5fx @iso (80 % peripheral dose)
Oligo final
Oligo final
Oligo final

Oligo final

  • 1.
  • 2.
    Contents  Oligometastatic Cancer–definition  Rationale for metastatic directed therapy  SABR –studies  Trials
  • 3.
    Definition  No thoughtful/formalstaging-UICC 8th edition doesn’t have a an assigned prognostic group  <=3 lesions outside pelvis  <=5 lesions limited to lymph nodes/bones  <=10 lesions with no visceral involvement  Select studies defining the same  Imaging also need to be standardized Tc99>>>PSMA PET-CT  Synchronous vs Metachronous ?
  • 7.
    Stereotactic Ablative Radiotherapy(SABR)  5 studies –retrospective small number  Most of the targets bones >>some visceral, nodes  Only take away message is that it’s safe  No G-III toxicity  Even G-II quite low  Local control pretty good –ablative  Freedom from androgen deprivation 2 studies managed for 2-3 years
  • 8.
    2 Trials  STOMP(Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence)  ORIOLE trial (Observation Versus Stereotactic Ablative RadiatIOn for OLigometastatic Prostate CancEr)
  • 11.
    Note  The STOMPtrial showed a trend towards delayed ADT, but failed to show a reduction in metastatic progression. An important limitation of both the STOMP and ORIOLE studies is that the investigators were unable to account for length-bias and may well have included metastatic patients with slower growing disease.
  • 14.
    (1) a methodof external beam radiotherapy (EBRT) that (2) accurately delivers a (3) high dose of irradiation in (4) one or few treatment fractions to an (5) extracranial target.  AAPM Task Group 101  ASTRO and ACR SBRT DEFINITION
  • 16.
    SBRT spine-mets  67yr old male case of Ca Prostate post-op with spine recurrence (cord compression)-D5-D6 level  Post tumor decompression/spine stabilization patient planned for SBRT to D5-D6 level  RT dose 30 Gy/ 5fx @iso (80 % peripheral dose)